Combination of analytics, research, and performance improvement
expertise to support evidence-based medical device and drug selection,
CHICAGO--(BUSINESS WIRE)--May 23, 2018--
Navigant (NYSE: NCI) and Lumere today announced a collaboration to help
healthcare providers implement evidence-based, technology-enabled
consulting solutions aimed at reducing clinical and financial variation.
The goal of the collaboration is to assist hospitals and health systems
with reducing unnecessary utilization of drugs and medical devices in
such areas as orthopedic, spine, cardiac, and surgical services.
suggests up to a quarter of overall healthcare expenditures are wasteful
and not associated with improved quality. A proven way to reduce waste
is to target unnecessary variation in clinical processes. However,
providers often lack the resources to analyze major clinical cost
factors necessary to drive action.
“For providers, the focus on reducing unwarranted utilization has only
intensified as operating margins dwindle and the pressure to reduce
costs while maintaining quality rises,” said Dave
Zito, managing director and Navigant’s Healthcare segment leader.
“We believe the combination of Lumere’s research and analytics
capabilities, and Navigant’s proven successes working with providers
nationwide, creates a unique clinical supply chain solution that can
drive sustainable quality and financial improvements.”
By providing both physicians and hospital leaders with clinically
derived, evidence-based data, Lumere accelerates their ability to reduce
unnecessary and costly clinical variation.
“We’re honored to collaborate with Navigant to help enable
evidence-based medicine that delivers clear clinical and financial
benefits,” said Hani Elias, JD, MPH, Lumere co-founder and CEO. “In our
experience, physicians are hungry for data that will help them make
decisions that are both patient-focused and cost-effective. Our
technology not only helps illuminate new opportunities, but also
provides caregivers data they’ve long sought to make informed decisions.”
By leveraging Lumere’s solutions both during and after Navigant
engagements, providers may also be better equipped to better:
Understand cost-reduction opportunities that are based on utilization
and unwarranted variation.
Engage physicians around opportunities to standardize to drugs and
devices that demonstrate clinically equivalent outcomes at a lower
Optimize the type and frequency of products used based on specific
patient circumstances and cases.
Improve the rigor of cost-management programs, such as value analysis.
A Navigant analysis suggests
U.S. hospitals could reduce their supply chain expenses by 18% without
Navigant’s Healthcare supply chain practice works with hospitals and
health systems nationwide to streamline clinical care pathways while
lowering the associated cost of treatment and creating an environment
that empowers those supporting it.
Navigant Consulting, Inc. (NYSE: NCI) is a specialized, global
professional services firm that helps clients take control of their
future. Navigant’s professionals apply deep industry knowledge,
substantive technical expertise, and an enterprising approach to help
clients build, manage, and/or protect their business interests. With a
focus on markets and clients facing transformational change and
significant regulatory or legal pressures, the firm primarily serves
clients in the healthcare, energy, and financial services industries.
Across a range of advisory, consulting, outsourcing, and
technology/analytics services, Navigant’s practitioners bring sharp
insight that pinpoints opportunities and delivers powerful results. More
information about Navigant can be found at navigant.com.
Lumere is at the forefront of clinical decision making for drugs and
devices, offering evidence-based solutions and services for all
providers that improve care and reduce cost across the patient journey.
For more information, visit lumere.com,
find us on LinkedIn,
follow @LumereHQ on
Twitter and like us on Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180523005220/en/
Navigant Investor Relations